Der Ploeg Leonardus H.T. Van Sells 38,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) insider Der Ploeg Leonardus H.T. Van sold 38,000 shares of the stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $30.09, for a total transaction of $1,143,420.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Der Ploeg Leonardus H.T. Van also recently made the following trade(s):

  • On Tuesday, September 25th, Der Ploeg Leonardus H.T. Van sold 31,800 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $29.80, for a total transaction of $947,640.00.

NASDAQ:RYTM opened at $31.34 on Friday. Rhythm Pharmaceuticals Inc has a 1 year low of $16.80 and a 1 year high of $37.23. The firm has a market capitalization of $1.02 billion and a P/E ratio of -11.07.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). Equities analysts anticipate that Rhythm Pharmaceuticals Inc will post -1.94 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its stake in Rhythm Pharmaceuticals by 110.5% in the 2nd quarter. Bank of America Corp DE now owns 6,251 shares of the company’s stock valued at $195,000 after buying an additional 3,282 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Rhythm Pharmaceuticals by 642.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,735 shares of the company’s stock valued at $273,000 after buying an additional 7,559 shares during the last quarter. Highland Capital Management LP acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at $313,000. Rhumbline Advisers acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at $357,000. Finally, TD Asset Management Inc. acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at $364,000. Institutional investors and hedge funds own 87.08% of the company’s stock.

RYTM has been the topic of several analyst reports. Morgan Stanley set a $38.00 price target on shares of Rhythm Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 7th. Zacks Investment Research lowered shares of Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. BidaskClub lowered shares of Rhythm Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 25th. Stifel Nicolaus initiated coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, September 14th. They set a “hold” rating and a $36.00 price target on the stock. Finally, Needham & Company LLC set a $42.00 price target on shares of Rhythm Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $38.60.

TRADEMARK VIOLATION WARNING: “Der Ploeg Leonardus H.T. Van Sells 38,000 Shares of Rhythm Pharmaceuticals Inc (RYTM) Stock” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/11/09/der-ploeg-leonardus-h-t-van-sells-38000-shares-of-rhythm-pharmaceuticals-inc-rytm-stock.html.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its peptide candidates include Setmelanotide, a melanocortin-4 receptor agonist, which is in Phase III clinical trial to treat POMC and leptin receptor deficiency obesity; and Phase II clinical trial for Bardet-Biedl and Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.

Read More: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply